Today’s N/R
PharmaDrug Engages Octagon Media and Affiliated Wall Street Reporter for Investor Marketing Campaign
2022-01-20 08:01 ET - News Release
Toronto, Ontario--(Newsfile Corp. - January 20, 2022) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, announces that it has engaged Octagon Media Corp to assist in a digital media advertising campaign coupled with an investor marketing program.
As compensation, Octagon Media Corp. will receive a payment of US$60,000 as well as 3,400,000 common shares of PharmaDrug. The shares will be subject to a statutory four month hold. The Company will also grant Octagon Media Corp incentive stock options to purchase up to 3,000,000 common shares in the capital of the Company at an exercise price of $0.05 CAD per share for a 12 month period.
Octagon Media Corp.'s services consist of the Wall Street Reporter and Next Super Stock platforms. The services will include investor conferences, features on the WallStreetReporter.com website, CEO podcast interviews as well a social media and targeted email distribution. The term of the contract is for six months.
Daniel Cohen, Chairman and CEO of PharmaDrug, commented, "We are extremely excited to be working with Jack Marks and the Wall Street Reporter. We believe the Company is well positioned to benefit from a wider U.S. investor audience due to its emerging biotech strategy and are confident The Wall Street Reporter can help us achieve that goal."
Following posting its shares on the OTCQB in October of 2021, the Company's common shares became DTC eligible last week, thereby increasing the accessibility of the common shares to U.S. investors.
About PharmaDrug Inc.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. PharmaDrug owns 100% of Pharmadrug Production GmbH ("Pharmadrug Production"), a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union. PharmaDrug acquired Sairiyo Therapeutics ("Sairiyo") in 2021, a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of Covid-19 and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms, and psilocybin mushrooms where federally legal, as natural based medicines.